Adrenocortical secondary prevention

_NOTOC_ Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Template:AR Mohammed Abdelwahed M.D[2] Template:Adrenocortical carcinoma secondary prevention

-Overview- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy.

-Adrenocortical carcinoma secondary prevention-

Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. Surveillance intervals may be increased to 6 months for the next 5 years. Surveillance should also include: Cross-sectional imaging of chest, abdomen, and pelvis The use of FDG-PET for lesions of an unclear nature Laboratory evaluation for steroid hormones Evaluation of side effects is also important in case of adjuvant mitotane therapy

-References- Template:Riflist